Kinex grants Hanmi exclusive rights to develop and commercialize KX01 (KX2-391) for all oncology indications in Korea, China and some Southeast Asian countries

Kinex Pharmaceuticals LLC

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Hanmi Pharmaceutical Co. Ltd.

South Korea / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced